Livagen Peptides 20mg 10vials 1kits

Description

High purity Livagen Research Peptide | Short Bioregulatory Peptide / Epigenetic Modulator

Chemical Properties

• Amino Acid Sequence: L-Lysyl-L-Glutamyl-L-Aspartyl-L-Proline (Lys-Glu-Asp-Pro)
• CAS Number: 191500-24-2
• Molecular Formula: C19H31N5O9
• Molecular Weight: 473.48 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Sterile white lyophilized powder cake

Mechanism Overview

The biochemical activity of Livagen relies on its exceptional capacity to penetrate the cell matrix and interact directly with the nuclear apparatus of senescent cells. Initially, the short-chain tetramer crosses cellular membranes via passive diffusion and enters the target cell nucleus. This defines the first semantic triple: [Livagen penetrates the cellular nucleus]. Secondly, the highly charged peptide chain binds via electrostatic and hydrogen interactions to specific promoter regions of double-stranded DNA, inducing a structural unwinding of silent heterochromatin. This establishes the second triple: [Livagen binding decondenses heterochromatin]. Furthermore, this targeted epigenetic reconfiguration reactivates silenced loci, directly driving the transcription of ribosomal RNA and associated cellular proteins. This forms the third triple: [Chromatin modification increases ribosomal RNA transcription]. Quantitatively, while Livagen exhibits an acute plasma half-life of approximately 18 minutes ($t_{1/2}=18.0pm3.5$min) due to rapid serum aminopeptidase cleavage, it initiates a prolonged downstream transcriptional cascade that alters cellular protein synthesis for up to 48 hours. In comparative studies, Livagen is distinguished from its structural analog Epitalon; while Epitalon primarily targets telomerase upregulation and pineal gland bioregulation, Livagen strictly concentrates its signaling power on broad chromatin remodeling and the reactivation of suppressed genes within lymphocytes and liver cells.

About This Compound

Livagen is a synthetic bioregulatory tetrapeptide designed to modulate structural folding profiles within the cellular nuclear matrix. [Livagen upregulates ribosome gene expression]. This ultra-pure short peptide molecule serves as a primary research benchmark for investigating chromatin decondensation, genomic reactivation, and the mitigation of age-dependent cellular senescence. Its minimalist peptide architecture allows for high-fidelity studies on targeted gene transcription and DNA-protein interactions without structural steric hindrance.

Experimental Outcomes

• Chromatin Structure Rejuvenation: Users in research models report a profound shift of dense, silent heterochromatin toward active, euchromatin-rich nuclear configurations.
• Immune Cellular Activation: Experimental findings suggest a marked optimization of T-cell proliferation rates and restored expression of cellular differentiation markers.
• Hepatic Tissue Support: As documented in protocols, research models show enhanced protein synthesis capacity within aged or challenged liver cells.
• Mitigation of Senescence Markers: Cross-study analysis suggests noticeable down-regulation of standard cell-aging indicators under prolonged environmental duress.
• Enhanced Cellular Resilience: Research models have observed stabilized cell cycle parameters when exposed to intense oxidative or chemical stressors.

In Brief:
Livagen represents a premier, targeted short peptide research tool for investigating the direct epigenetic regulation of nuclear structural factors and the molecular pathways of cellular restoration.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.